William Lewis Sells 17,442 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 17,442 shares of the stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $66.97, for a total transaction of $1,168,090.74. Following the sale, the chief executive officer now directly owns 316,744 shares in the company, valued at $21,212,345.68. This trade represents a 5.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

William Lewis also recently made the following trade(s):

• On Wednesday, May 14th, William Lewis sold 3,771 shares of Insmed stock. The stock was sold at an average price of $65.61, for a total transaction of $247,415.31.
• On Thursday, May 1st, William Lewis sold 6,830 shares of Insmed stock. The stock was sold at an average price of $72.57, for a total transaction of $495,653.10.
• On Tuesday, April 15th, William Lewis sold 6,830 shares of Insmed stock. The stock was sold at an average price of $70.16, for a total transaction of $479,192.80.
• On Monday, March 17th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.03, for a total transaction of $1,444,312.50.
• On Monday, March 3rd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.79, for a total transaction of $1,458,562.50.
• On Tuesday, February 18th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $81.03, for a total transaction of $1,519,312.50.

Insmed Stock Up 1.3%

Shares of Insmed stock opened at $68.12 on Friday. The stock’s fifty day moving average is $71.57 and its 200-day moving average is $73.10. The firm has a market capitalization of $12.41 billion, a PE ratio of -12.19 and a beta of 0.84. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). The company had revenue of $92.82 million for the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same period last year, the firm earned ($1.06) earnings per share. Equities analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on INSM shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. Wells Fargo & Company increased their target price on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Truist Financial increased their target price on shares of Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research report on Friday, February 21st. HC Wainwright reiterated a “buy” rating and issued a $90.00 target price on shares of Insmed in a research report on Monday, May 12th. Finally, UBS Group decreased their target price on shares of Insmed from $110.00 to $109.00 and set a “buy” rating for the company in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.63.

Institutional Investors Weigh In On Insmed

A number of institutional investors and hedge funds have recently modified their holdings of INSM. Cullen Frost Bankers Inc. raised its position in shares of Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 221 shares during the period. Elequin Capital LP purchased a new position in shares of Insmed during the fourth quarter valued at $28,000. Steward Partners Investment Advisory LLC grew its holdings in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 163 shares in the last quarter. V Square Quantitative Management LLC raised its position in Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 248 shares during the period. Finally, Spire Wealth Management purchased a new stake in Insmed in the 4th quarter worth about $47,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.